Cure My Disease

Don't miss your cure!

 Log in / Sign up

Walking memory tests may reveal early Parkinson's clues

NCT ID NCT07827963

Knowledge-focused Sponsor: IRCCS San Raffaele Roma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are studying whether navigational memory fades before other spatial memory in people with Parkinson's disease and related conditions. The pilot includes 80 participants: those with mild or advanced Parkinson's, those with parkinsonism, and healthy volunteers. Participants complete memory tasks on foot and at a table while wearable sensors record their walking and eye-tracking glasses capture where they look. Assessments repeat at 12 and 24 months to see how memory, movement, and gaze relate over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
multimodal visuospatial and topographical memory assessment
What this could lead to
If navigational memory declines earlier than other spatial memory, doctors could one day use simple walking-and-memory tests to spot Parkinson's progression sooner and tailor rehabilitation.
What could go wrong
This is a small observational pilot with 80 participants, so it can only suggest patterns, not prove cause or predict individual outcomes. The findings may not apply to all people with Parkinson's or parkinsonism.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Parkinson's disease, Parkinsonism, and healthy participants

Ages

35 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Male and female subjects aged between 35 and 80 years; * Diagnosis of Parkinson's disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank criteria; * Diagnosis of primary atypical parkinsonism MSA-P, according to the Second Consensus Statement on the Diagnosis of Multiple System Atrophy; * Diagnosis of primary atypical parkinsonism PSP-P, according to the Movement Disorder Society criteria for Progressive Supranuclear Palsy; * Modified Hoehn and Yahr stage between 1 and 3 during the "ON" phase (Hoehn and Yahr, 1967); * Cognitive screening with the Montreal Cognitive Assessment (MoCA) score \> 17; * Mini-Mental State Examination (MMSE) score ≥ 24 (Folstein et al., 1975); * Ability to walk independently for 10 meters without assistive devices; * Ability to understand and sign the informed consent form; * Ability to comply with study procedures. Exclusion Criteria * Diagnosis of neurological disorders other than Multiple System Atrophy (MSA) and Parkinson's disease; * Depressive disorders or Beck Depression Inventory-II (BDI-II) score \> 20; * Musculoskeletal disorders that could impair gait performance. The study will enroll 20 healthy subjects, matched by age and sex with patients affected by Parkinson's disease (PD) and atypical parkinsonism who will be recruited into the study. The same inclusion criteria will be applied to both groups of patients with Multiple System Atrophy (MSA) and Parkinson's disease. The exclusion criteria will be: * Diagnosis of neurological disorders; * Depressive disorders or Beck Depression Inventory-II (BDI-II) score \> 20; * Musculoskeletal disorders that could impair gait performance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction multiple system atrophy Parkinson disease parkinsonian disorder progressive supranuclear palsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild cognitive impairment Multiple system atrophy Parkinson's disease Parkinsonism Progressive supranuclear palsy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS San Raffaele Cassino - CTC Via G. di Biasio, 1

    Cassino, Frosinone, 03043, Italy

  • University of Roma La Sapienza Department of Psychology University of Rome

    Roma, Roma, 00185, Italy

  • University of Roma La Sapienza Department of Psychology University of Rome 00185, Rome

    Roma, Roma, 00185, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.